Annual CFO
-$47.42 M
-$14.94 M-46.00%
31 December 2023
Summary:
Armata Pharmaceuticals annual cash flow from operations is currently -$47.42 million, with the most recent change of -$14.94 million (-46.00%) on 31 December 2023. During the last 3 years, it has fallen by -$29.15 million (-159.57%). ARMP annual CFO is now -7725.58% below its all-time high of -$606.00 thousand, reached on 31 December 2000.ARMP Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$8.86 M
+$1.31 M+12.91%
30 September 2024
Summary:
Armata Pharmaceuticals quarterly cash flow from operations is currently -$8.86 million, with the most recent change of +$1.31 million (+12.91%) on 30 September 2024. Over the past year, it has increased by +$824.00 thousand (+8.51%). ARMP quarterly CFO is now -270.23% below its all-time high of $5.21 million, reached on 30 September 2000.ARMP Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$37.73 M
+$824.00 K+2.14%
30 September 2024
Summary:
Armata Pharmaceuticals TTM cash flow from operations is currently -$37.73 million, with the most recent change of +$824.00 thousand (+2.14%) on 30 September 2024. Over the past year, it has increased by +$12.07 million (+24.24%). ARMP TTM CFO is now -6126.07% below its all-time high of -$606.00 thousand, reached on 31 December 2000.ARMP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARMP Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.0% | +8.5% | +24.2% |
| 3 y3 years | -159.6% | -78.5% | -77.3% |
| 5 y5 years | -405.5% | -94.1% | -154.9% |
ARMP Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -159.6% | at low | -152.2% | +49.6% | -77.3% | +25.2% |
| 5 y | 5 years | -405.5% | at low | -224.8% | +49.6% | -156.7% | +25.2% |
| alltime | all time | -7725.6% | at low | -270.2% | +49.6% | -6126.1% | +25.2% |
Armata Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.86 M(-12.9%) | -$37.73 M(-2.1%) |
| June 2024 | - | -$10.18 M(-3.8%) | -$38.55 M(-4.7%) |
| Mar 2024 | - | -$10.58 M(+30.6%) | -$40.44 M(-14.7%) |
| Dec 2023 | -$47.42 M(+46.0%) | -$8.11 M(-16.3%) | -$47.42 M(-4.8%) |
| Sept 2023 | - | -$9.69 M(-19.7%) | -$49.80 M(-1.3%) |
| June 2023 | - | -$12.06 M(-31.4%) | -$50.45 M(+8.4%) |
| Mar 2023 | - | -$17.57 M(+67.6%) | -$46.54 M(+43.3%) |
| Dec 2022 | -$32.48 M(+37.8%) | -$10.48 M(+1.5%) | -$32.48 M(+6.2%) |
| Sept 2022 | - | -$10.33 M(+26.8%) | -$30.59 M(+21.3%) |
| June 2022 | - | -$8.15 M(+131.8%) | -$25.23 M(+16.7%) |
| Mar 2022 | - | -$3.52 M(-59.1%) | -$21.61 M(-8.3%) |
| Dec 2021 | -$23.57 M(+29.0%) | -$8.60 M(+73.2%) | -$23.57 M(+10.8%) |
| Sept 2021 | - | -$4.96 M(+9.4%) | -$21.28 M(+5.4%) |
| June 2021 | - | -$4.54 M(-17.1%) | -$20.20 M(+3.5%) |
| Mar 2021 | - | -$5.47 M(-13.1%) | -$19.51 M(+6.8%) |
| Dec 2020 | -$18.27 M(+17.3%) | -$6.30 M(+62.4%) | -$18.27 M(+24.3%) |
| Sept 2020 | - | -$3.88 M(+0.6%) | -$14.70 M(-4.5%) |
| June 2020 | - | -$3.86 M(-8.9%) | -$15.38 M(-11.4%) |
| Mar 2020 | - | -$4.23 M(+55.1%) | -$17.36 M(+11.4%) |
| Dec 2019 | -$15.58 M(+66.1%) | -$2.73 M(-40.2%) | -$15.58 M(+5.3%) |
| Sept 2019 | - | -$4.57 M(-21.6%) | -$14.80 M(+23.8%) |
| June 2019 | - | -$5.83 M(+137.0%) | -$11.96 M(+44.0%) |
| Mar 2019 | - | -$2.46 M(+26.1%) | -$8.30 M(-11.5%) |
| Dec 2018 | -$9.38 M(+2.1%) | -$1.95 M(+13.2%) | -$9.38 M(-4.3%) |
| Sept 2018 | - | -$1.72 M(-20.7%) | -$9.80 M(+13.0%) |
| June 2018 | - | -$2.17 M(-38.5%) | -$8.67 M(-8.0%) |
| Mar 2018 | - | -$3.54 M(+49.3%) | -$9.43 M(+2.6%) |
| Dec 2017 | -$9.19 M(-13.3%) | -$2.37 M(+299.5%) | -$9.19 M(+10.5%) |
| Sept 2017 | - | -$593.00 K(-79.8%) | -$8.32 M(-23.4%) |
| June 2017 | - | -$2.93 M(-11.2%) | -$10.86 M(+0.4%) |
| Mar 2017 | - | -$3.30 M(+120.2%) | -$10.82 M(+2.0%) |
| Dec 2016 | -$10.61 M(+8.4%) | -$1.50 M(-52.2%) | -$10.61 M(-7.2%) |
| Sept 2016 | - | -$3.13 M(+8.3%) | -$11.43 M(+5.9%) |
| June 2016 | - | -$2.89 M(-6.3%) | -$10.79 M(+2.2%) |
| Mar 2016 | - | -$3.08 M(+33.1%) | -$10.56 M(+8.0%) |
| Dec 2015 | -$9.78 M(-22.2%) | -$2.32 M(-7.2%) | -$9.78 M(-8.3%) |
| Sept 2015 | - | -$2.50 M(-6.2%) | -$10.66 M(-1.2%) |
| June 2015 | - | -$2.66 M(+15.5%) | -$10.79 M(-3.5%) |
| Mar 2015 | - | -$2.31 M(-28.0%) | -$11.19 M(-11.0%) |
| Dec 2014 | -$12.57 M(+99.8%) | -$3.20 M(+21.8%) | -$12.57 M(+16.6%) |
| Sept 2014 | - | -$2.63 M(-14.0%) | -$10.78 M(+1.2%) |
| June 2014 | - | -$3.05 M(-17.3%) | -$10.65 M(+20.2%) |
| Mar 2014 | - | -$3.69 M(+161.4%) | -$8.86 M(+40.9%) |
| Dec 2013 | -$6.29 M(+47.0%) | -$1.41 M(-43.4%) | -$6.29 M(+28.9%) |
| Sept 2013 | - | -$2.49 M(+96.8%) | -$4.88 M(+104.5%) |
| June 2013 | - | -$1.27 M(+13.2%) | -$2.39 M(+113.2%) |
| Mar 2013 | - | -$1.12 M(-189.7%) | -$1.12 M(-79.1%) |
| Dec 2012 | -$4.28 M(-58.5%) | - | - |
| Sept 2009 | - | $1.25 M(-186.5%) | -$5.36 M(-45.5%) |
| June 2009 | - | -$1.44 M(+11.4%) | -$9.83 M(+22.1%) |
| Mar 2009 | - | -$1.29 M(-66.5%) | -$8.05 M(-21.8%) |
| Dec 2008 | -$10.30 M | -$3.87 M(+19.9%) | -$10.30 M(+1.6%) |
| Sept 2008 | - | -$3.23 M(-1063.3%) | -$10.14 M(-9.3%) |
| June 2008 | - | $335.00 K(-109.4%) | -$11.18 M(-22.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$3.54 M(-4.2%) | -$14.39 M(+3.7%) |
| Dec 2007 | -$13.88 M(+19.3%) | -$3.70 M(-13.3%) | -$13.88 M(+12.9%) |
| Sept 2007 | - | -$4.27 M(+48.6%) | -$12.29 M(+12.7%) |
| June 2007 | - | -$2.87 M(-5.4%) | -$10.91 M(-7.6%) |
| Mar 2007 | - | -$3.04 M(+43.7%) | -$11.80 M(+1.4%) |
| Dec 2006 | -$11.64 M(-29.0%) | -$2.11 M(-26.6%) | -$11.64 M(-6.7%) |
| Sept 2006 | - | -$2.88 M(-23.4%) | -$12.48 M(-17.8%) |
| June 2006 | - | -$3.76 M(+30.9%) | -$15.19 M(-4.9%) |
| Mar 2006 | - | -$2.88 M(-2.7%) | -$15.97 M(-2.6%) |
| Dec 2005 | -$16.39 M(+5.6%) | -$2.96 M(-47.1%) | -$16.39 M(-1.5%) |
| Sept 2005 | - | -$5.59 M(+23.0%) | -$16.65 M(+0.9%) |
| June 2005 | - | -$4.55 M(+38.1%) | -$16.50 M(+7.1%) |
| Mar 2005 | - | -$3.29 M(+2.6%) | -$15.41 M(-0.7%) |
| Dec 2004 | -$15.52 M(+38.2%) | -$3.21 M(-41.0%) | -$15.52 M(-8.7%) |
| Sept 2004 | - | -$5.45 M(+57.7%) | -$17.00 M(+14.9%) |
| June 2004 | - | -$3.45 M(+1.3%) | -$14.79 M(+1.4%) |
| Mar 2004 | - | -$3.41 M(-27.2%) | -$14.58 M(+29.9%) |
| Dec 2003 | -$11.23 M(-44.1%) | -$4.68 M(+44.3%) | -$11.23 M(-7.4%) |
| Sept 2003 | - | -$3.25 M(+0.0%) | -$12.12 M(-4.0%) |
| June 2003 | - | -$3.24 M(+5591.2%) | -$12.63 M(-10.8%) |
| Mar 2003 | - | -$57.00 K(-99.0%) | -$14.15 M(-29.6%) |
| Dec 2002 | -$20.10 M(-14.6%) | -$5.58 M(+48.7%) | -$20.10 M(-8.4%) |
| Sept 2002 | - | -$3.75 M(-21.3%) | -$21.94 M(-8.4%) |
| June 2002 | - | -$4.77 M(-20.6%) | -$23.95 M(-2.8%) |
| Mar 2002 | - | -$6.00 M(-19.1%) | -$24.64 M(+4.6%) |
| Dec 2001 | -$23.54 M(+3785.0%) | -$7.42 M(+28.8%) | -$23.54 M(+38.4%) |
| Sept 2001 | - | -$5.76 M(+5.6%) | -$17.01 M(+181.4%) |
| June 2001 | - | -$5.45 M(+11.1%) | -$6.04 M(+130.9%) |
| Mar 2001 | - | -$4.91 M(+452.5%) | -$2.62 M(+331.9%) |
| Dec 2000 | -$606.00 K(-94.3%) | -$888.50 K(-117.1%) | -$606.00 K(-62.5%) |
| Sept 2000 | - | $5.21 M(-357.0%) | -$1.62 M(-83.5%) |
| June 2000 | - | -$2.03 M(-30.1%) | -$9.82 M(-7.3%) |
| Mar 2000 | - | -$2.90 M(+52.5%) | -$10.60 M(-0.0%) |
| Dec 1999 | -$10.60 M(+82.8%) | -$1.90 M(-36.7%) | -$10.60 M(+100.0%) |
| Sept 1999 | - | -$3.00 M(+7.1%) | -$5.30 M(-1.9%) |
| June 1999 | - | -$2.80 M(-3.4%) | -$5.40 M(-8.5%) |
| Mar 1999 | - | -$2.90 M(-185.3%) | -$5.90 M(+1.7%) |
| Dec 1998 | -$5.80 M(-53.6%) | $3.40 M(-209.7%) | -$5.80 M(-55.0%) |
| Sept 1998 | - | -$3.10 M(-6.1%) | -$12.90 M(+7.5%) |
| June 1998 | - | -$3.30 M(+17.9%) | -$12.00 M(-0.8%) |
| Mar 1998 | - | -$2.80 M(-24.3%) | -$12.10 M(-3.2%) |
| Dec 1997 | -$12.50 M(+20.2%) | -$3.70 M(+68.2%) | -$12.50 M(+8.7%) |
| Sept 1997 | - | -$2.20 M(-35.3%) | -$11.50 M(+0.9%) |
| June 1997 | - | -$3.40 M(+6.3%) | -$11.40 M(+3.6%) |
| Mar 1997 | - | -$3.20 M(+18.5%) | -$11.00 M(+5.8%) |
| Dec 1996 | -$10.40 M(+22.4%) | -$2.70 M(+28.6%) | -$10.40 M(+9.5%) |
| Sept 1996 | - | -$2.10 M(-30.0%) | -$9.50 M(+1.1%) |
| June 1996 | - | -$3.00 M(+15.4%) | -$9.40 M(+8.0%) |
| Mar 1996 | - | -$2.60 M(+44.4%) | -$8.70 M(+2.4%) |
| Dec 1995 | -$8.50 M(+18.1%) | -$1.80 M(-10.0%) | -$8.50 M(+26.9%) |
| Sept 1995 | - | -$2.00 M(-13.0%) | -$6.70 M(+42.6%) |
| June 1995 | - | -$2.30 M(-4.2%) | -$4.70 M(+95.8%) |
| Mar 1995 | - | -$2.40 M | -$2.40 M |
| Dec 1994 | -$7.20 M(+63.6%) | - | - |
| Dec 1993 | -$4.40 M | - | - |
FAQ
- What is Armata Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals annual CFO year-on-year change?
- What is Armata Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals quarterly CFO year-on-year change?
- What is Armata Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Armata Pharmaceuticals?
- What is Armata Pharmaceuticals TTM CFO year-on-year change?
What is Armata Pharmaceuticals annual cash flow from operations?
The current annual CFO of ARMP is -$47.42 M
What is the all time high annual CFO for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high annual cash flow from operations is -$606.00 K
What is Armata Pharmaceuticals annual CFO year-on-year change?
Over the past year, ARMP annual cash flow from operations has changed by -$14.94 M (-46.00%)
What is Armata Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ARMP is -$8.86 M
What is the all time high quarterly CFO for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high quarterly cash flow from operations is $5.21 M
What is Armata Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ARMP quarterly cash flow from operations has changed by +$824.00 K (+8.51%)
What is Armata Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ARMP is -$37.73 M
What is the all time high TTM CFO for Armata Pharmaceuticals?
Armata Pharmaceuticals all-time high TTM cash flow from operations is -$606.00 K
What is Armata Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ARMP TTM cash flow from operations has changed by +$12.07 M (+24.24%)